Similar companies
Income Statement (USD)
| Q1 '24 | QoQ | |
|---|---|---|
| Revenue | 2.68B | 7.8% |
| Gross Profit | 1.99B | 17.1% |
| Cost of Revenue | 685M | 12.3% |
| Operating expense | 1.21B | 3.8% |
| Net Income | 1.1B | 13.5% |
| EBITDA | 1.14B | 12% |
Balance Sheet (USD)
| Q1 '24 | QoQ | |
|---|---|---|
| Total Assets | 23.9B | 5.2% |
| Total Liabilities | 5.37B | 4.3% |
| Total Equity | 18.5B | 5.5% |
| Shares Outstanding | 258M | 0.2% |
Cash Flow (USD)
| Q1 '24 | QoQ | |
|---|---|---|
| Cash from operations | 1.31B | 456.9% |
| Cash from investing | -2.14B | 141% |
| Cash from financing | -358M | 198.4% |
EPS
Financial Highlights for Vertex Pharmaceuticals in Q1 '24
Vertex Pharmaceuticals reported a revenue of 2.68B, which is a 7.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 1.99B, marking a 17.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 685M, a -12.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.21B, showing a -3.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 1.1B, showing a 13.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 1.14B, showing a 12% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Vertex Pharmaceuticals with growth in revenue, gross profit, and net income.